European CHMP recommends approval of fenfluramine (Fintepla) for the treatment of seizures associated with Dravet syndrome

Fenfluramine is intended for use as an add-on therapy to other anti-epileptics for patients 2 years of age and older. Its precise mechanism of action is unknown, but it increases stimulation of some brain 5-HT receptors, and acts on the sigma-1 receptor.

Source:

European Medicines Agency